Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: do we really need sodium increase, especially in sepsis? Reply
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: do we really need sodium increase, especially in sepsis? Reply ; volume:27 ; number:1 ; day:8 ; month:6 ; year:2023 ; pages:1-2 ; date:12.2023
Critical care ; 27, Heft 1 (8.6.2023), 1-2, 12.2023
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13054-023-04513-7
- URN
-
urn:nbn:de:101:1-2023091615340094449934
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mårtensson, Johan
- Bellomo, Rinaldo
- SpringerLink (Online service)
Other Objects (12)
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Acute renal failure in the critically ill : with 27 tables
Correspondence regarding the article by Murugan et al. on “Precision net ultrafiltration dosing in continuous kidney replacement therapy: a practical approach”
Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Acute renal failure in the critically ill : with 27 tables
Correspondence regarding the article by Murugan et al. on “Precision net ultrafiltration dosing in continuous kidney replacement therapy: a practical approach”
Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Acute renal failure in the critically ill : with 27 tables
Correspondence regarding the article by Murugan et al. on “Precision net ultrafiltration dosing in continuous kidney replacement therapy: a practical approach”
Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage